Search trials – HealthDB

Активни: Recruiting ×

Намерени 4,436 изпитвания Стр. 11 от 222

Recruiting Phase 1

A Phase 1 Study of AIR-001 in Adults with AATD.

Alpha-1 Antitrypsin Deficiency

Trial status: Authorised

Начало: 17.04.2026 Възраст: от 18 г.

Germany, Netherlands, Portugal +1 Airna Corp. 2025-523558-14-00

Recruiting Phase 4

CoCo3 - Comprehensive Health Effects of Combined Contraceptives: a 12-month randomized, controlled, open-label trial of E4+DRSP, EE20μg+DRSP and DRSP-only

Contraception

Trial status: Authorised 12-month use of study preparation, endpoint visit

Начало: 17.04.2026 Възраст: 18–64 г.

Finland Pohjois-Pohjanmaan hyvinvointialue, University Of Oulu 2025-523359-71-00

Recruiting Phase 2

IFCT-2502 LIMPID Phase II trial assessing 1st line and 2nd line treatment in patients with advanced Non-Small Cell Lung Cancer and Interstitial Lung Disease

Non Small Cell Lung Cancer Interstitial Lung Disease

Trial status: Authorised Progression-free survival, Duration of response, Overall survival, Best Overall Response, DCR at 8 weeks assessed by Independent Central Review (1st line part) and by investigators according to RECIST 1.1 (2nd line part), PFS, duration of response, OS, overall response rate (ORR) according to ILDs pattern on CT scan (centralized review) and severity (VC/DLCO)., Efficacy (PFS, duration of response, OS and Best Overall Response) and respiratory evolution (number of exacerbations of ILD) with or without anti-fibrosing treatment., Overall health status assessed using the FACT-L questionnaire, Incidence, nature, and severity of adverse events, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 6.0, 2nd line: Incidence, nature, and severity of immune related adverse events, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0 (NCI CTCAE v6.0). 1rst line : The primary endpoint is Disease control rate define by the % of patient with a stable (SD), partial response (PR) or complete response (CR) on CT scanner evaluation at 8 weeks assessed by investigators according to RECIST 1.1., 2nd line : The primary outcome is the treatment related respiratory worsening leading to discontinuation of treatment during the first 6 months

Начало: 17.04.2026 Възраст: от 18 г.

France Intergroupe Francophone De Cancerologie Thoracique 2025-522790-10-00

Recruiting Phase 2

A Multicentre, Open-Label Study Evaluating the Safety, Tolerability and Efficacy of MaaT013 in Ruxolitinib-Refractory or Intolerant Paediatric and Adolescent participants with Gastrointestinal Acute Graft-versus-Host Disease

Gastrointestinal Acute Graft-versus-Host Disease (GI-aGvHD)

Trial status: Authorised Proportion of participants achieving complete response (CR), very good partial response (VGPR) or partial response (PR) for GI at D28, D56, M3, M6 and M12 assessed by IRC and investigator, without requirement for additional systemic therapies prior to the assessment time point., Proportion of participants achieving CR, VGPR or PR for all organs at D28, D56, M3, M6 and M12 assessed by IRC and investigator, without requirement for additional systemic therapies prior to the assessment time point., DOR is assessed for responders only and is defined as the time from first response (at least PR) until aGvHD progression (loss of at least PR compared to baseline, confirmed with 2 evaluations), or the starting date of additional systemic therapies for aGvHD. Onset of cGvHD, or death without prior observation of aGvHD progression are considered as competing risks. DOR will be evaluated for both GI and overall aGvHD, until M12., OS is defined as the time from the date of first MaaT013 administration to the date of death due to any cause., PFS is defined as the time from first MaaT013 administration to the date of underlying malignancy relapse, progression or death (all causes). PFS will be evaluated up to M12., TTP is defined as the time from first MaaT013 administration to the date of underlying malignancy relapse or progression. TTP will be evaluated up to M12., SFR is defined as the number and percentage of participants who are steroid-free, defined by a daily dose of CS ≤ 0.25 mg/kg/day (methylprednisolone equivalent dose). Steroid-free rate at D28, D56, M3, M6, and M12 will be provided. SFR will be evaluated up to M12., Cumulative total dose of CS in mg/kg from date of first MaaT013 administration to D28, D56, M3, M6, and M12 will be derived and summarized., Number and percentage of participants who definitively tapered off CS at M12., Proportion of participants with cGvHD, defined as the diagnosis of any cGvHD, including mild, moderate or severe, up to M12 (NIH criteria). Co-primary: From inclusion to Month 6 (M6): Incidence of all AEs treatment-emergent AEs (TEAEs), serious AEs (SAEs), and assessment of all safety parameters (physical examinations, vital signs and laboratory clinically significant abnormalities)., Co-Primary: From M6 to M12, incidence of SAEs and AESIs only., Co-Primary: A comprehensive and detailed analysis of the nature, severity and frequency of AEs and SAEs will be performed., Co-Primary: 1) Retention time ▪ Proportion of participants able to retain MaaT013 for at least 30 min. ▪ Proportion of participants able to retain MaaT013 for at least 1h. ▪ Proportion of participants able to retain MaaT013 for at least 2h., Co-Primary: 2) Stress/anxiety evaluated with the depression anxiety stress scale, Co-Primary: 3) Procedure-related AEs ▪ Solicited TEAEs related to administration procedure will be collected within 72h after each MaaT013 administration, Co-Primary: 4) Factors compromising the administration of the study drug ▪ TEAEs leading to treatment discontinuation, interruption and postponement will be collected.

Начало: 17.04.2026 Възраст: 18–64 г.

France, Italy, Netherlands +1 MaaT PHARMA 2025-524302-15-00

Recruiting Phase 3

A Phase 3, Randomized, Open-Label Study of INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum Resistant Ovarian Cancer With Cyclin E1 Overexpression (MAESTRA 2)

Ovarian cancer

Trial status: Authorised Key Secondary 1. Objective response by BICR, defined as having a best overall response of CR or PR, as determined by BICR per RECIST v1.1., Secondary 2. DOR by BICR, defined as the time from the earliest date of CR or PR until the earliest date of disease progression, as determined by BICR per RECIST v1.1, or death due to any cause, whichever occurs first., Secondary 3. PFS by investigator, defined as the time from the date of randomization until the earliest date of disease progression, as determined by investigator assessment per RECIST v1.1, or death due to any cause, whichever occurs first., Secondary 4. Objective response by investigator, defined as having a best overall response of CR or PR, as determined by investigator assessment per RECIST v1.1., Secondary 5. DOR by investigator, defined as the time from the earliest date of CR or PR until the earliest date of disease progression, as determined by investigator assessment per RECIST v1.1, or death due to any cause, whichever occurs first., Secondary 6. AEs, assessed by physical examinations, evaluating changes in vital signs and ECGs, and through clinical laboratory blood sample evaluations., Secondary 7. Treatment interruptions, dose reductions, and discontinuation of study treatment due to AEs., Secondary 8. HRQoL, assessed by changes from baseline in EORTC QLQ-C30, EORTC QLQ-OV28, and EQ-5D-5L questionnaire scores 1. PFS by BICR, defined as the time from the date of randomization until the earliest date of disease progression as determined by BICR per RECIST v1.1, or death due to any cause, whichever occurs first, 2. OS, defined as the time from the date of randomization until death due to any cause.

Начало: 17.04.2026 Възраст: от 18 г.

Belgium, France, Germany +4 Incyte Corp. 2025-522748-42-00

Recruiting Phase 4

Effects of CLADribine tablets on the Immune Synapse, in Relapsing Multiple Sclerosis (RMS) patients_CLADIS.

Multiple Sclerosis

Trial status: Authorised Change in the expression of the co-stimulatory and adhesion molecules comprising the immune synapse in the relevant subpopulations of the adaptive and innate immune system, at 6- months of treatment, relative to baseline, Change in the ARR at year 1, relative to the 12-month pre-treatment period, Change in EDSS at the end of year 1, compared to baseline, Change in T25FW at the end of year 1, compared to baseline, Change in 9HPT at the end of year 1, compared to baseline, Number of T1 lesions (Gd+ and black holes) at the end of year 1, compared to baseline, Number of T2 lesions (total, new/enlarging) at the end of year 1, compared to baseline, Number CUA at the end of year 1, compared to baseline, Proportion of patients with NEDA-3 at the end of year 1, Proportion of patients with MEDA-3 at the end of year 1, Correlation of changes in the expression of Immune Synapse molecules in the immune cell populations of interest, with clinical outcomes at the end of year 1, Correlation of changes in the expression of Immune Synapse molecules in the immune cell populations of interest, with MRI outcomes at the end of year 1 Change in the expression of the co-stimulatory and adhesion molecules comprising the immune synapse in the relevant subpopulations of the adaptive and innate immune system, at 12- months of treatment, relative to baseline

Начало: 17.04.2026 Възраст: 18–64 г.

Greece Aristotle University Of Thessaloniki 2025-521910-24-00

Recruiting Phase 3

Efficacy and safety of NNC0487-0111 compared to placebo on morbidity and mortality in people with heart failure with preserved or mildly reduced ejection fraction and obesity (HF-POLARIS).

HFpEF or HFmrEF and obesity

Trial status: Authorised Time to first occurrence of a composite HF and MACE endpoint consisting of: CV death, HF hospitalisation or urgent HF visit, Nonfatal MI, Nonfatal stroke, Change in KCCQ-CSS for participants with baseline KCCQ‑CSS score

Начало: 17.04.2026 Възраст: от 18 г.

Czech Republic, France, Germany +2 Novo Nordisk A/S 2025-523717-29-00

Recruiting Phase 3

A Phase 3, Multicenter, Open-Label, Randomized Trial to Compare the Efficacy and Safety of Elritercept versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes in ESA-naïve Adult Participants Who Require Red Blood Cell Transfusions

Myelodysplastic neoplasms/syndromes (MDS)

Trial status: Authorised Key Secondary Endpoint: Proportion of participants who are RBC-TI for any consecutive ≥16-week period from C1D1 through Week 24., Key Secondary Endpoint: Proportion of participants who are RBC-TI for any consecutive ≥12-week period from C1D1 through Week 24., Key Secondary Endpoint: Proportion of participants who are RBC-TI for a consecutive 24-week period from C1D1., For further details please refer to the Protocol Proportion of participants who are RBC-TI for any consecutive ≥12-week period from Cycle 1 Day 1 (C1D1) through Week 24 with concurrent mean Hgb increase ≥1.5 g/dL from baseline

Начало: 17.04.2026 Възраст: от 18 г.

Belgium, Greece, Lithuania +3 Takeda Development Center Americas Inc. 2025-523544-12-00

Recruiting Phase 2

Omalizumab for monotherapy treatment of patients with food allergies to plant-based foods due to sensitization to LTP and profilin

Categoria 2 Patients with vegetable allergies due to sensitization to profilin and LTPs and those patients in whom sublingual immunotherapy with Pru p 3 (peach LTP) has not been effective were evaluated in a before-after study to assess changes in clinical reactivity to LTP (peach) and profilin (melon) and immunological changes after intervention with omalizumab.

Trial status: Authorised Clinical efficacy defined as an increase in the amounts of at least 1 other food related to sensitisation to LTP (quantitative)., Clinical efficacy defined as an increase in the amounts of at least 1 more food related to sensitisation to profilin (quantitative)., Analysis of quality of life before and after treatment with omalizumab. Clinical efficacy defined as an increase in the amounts of peach in patients allergic to LTP and melon in patients allergic to apple tolerated in PPO after 16 weeks of treatment with omalizumab.

Начало: 17.04.2026 Възраст: 18–64 г.

Spain Fundacion Publica Andaluza Para La Investigacion De Mal 2025-524629-42-00

Recruiting

Poi for Mama: a Pilot to Improve Maternal Microbiome and Gestational Diabetes Risk

Gestational Diabetes Mellitus (GDM) Pregnancy

This investigator-initiated, non-randomized pilot study evaluates the effect of daily consumption of fermented poi on the maternal microbiome and gestational diabetes risk during pregnancy. Fifty pregnant participants between approximately 12 and 24 weeks of gestation will receive one pound of poi daily for four weeks, accompanied by culturally tailored nutrition education delivered via secure text messaging. Changes in vaginal, oral, and rectal microbiome composition, diet quality, gestational diabetes diagnosis, and pregnancy-related outcomes will be assessed and compared with matched controls derived from an existing cohort. This study aims to inform the feasibility and design of a larger culturally grounded dietary intervention for gestational diabetes prevention.

Начало: 16.04.2026 Край: 31.01.2027 Възраст: от 18 г.

United States University of Hawaii NCT07446205

Recruiting Phase 2

Inflammation in Primary and Secondary Malignancies of the Central Nervous System Using [C-11]-CS1P1

Central Nervous System Cancer Brain Metastases

Adult patients with primary or secondary central nervous system malignancies will be invited to undergo a baseline \[C-11\]-CS1P1 PET scan and a follow-up scan within 24 months of the baseline scan (preferably within 6-months post-treatment).The study will describe patterns of tracer uptake in tumors and normal brain and explore how these patterns relate to MRI findings, treatments received, and clinical outcomes.

Начало: 16.04.2026 Край: 30.06.2033 Възраст: от 18 г.

United States Washington University School of Medicine NCT07462507

Recruiting Phase 1

Inhaled Nitric Oxide in Acute Ischemic Stroke Patients Undergoing Mechanical Thrombectomy

Cerebrovascular Disorders Acute Cerebrovascular Disease

The purpose of this study is to determine the safety and feasibility of using inhaled nitric oxide (iNO) in patients undergoing intra-arterial mechanical thrombectomy (blood clot extraction or IAMT) for treatment of acute ischemic (non-bleeding) stroke (AIS).

Начало: 16.04.2026 Край: 01.12.2028 Възраст: 18–80 г.

United States Wake Forest University Health Sciences NCT05871606

Recruiting Phase 2

A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis

Myasthenia Gravis, Generalized

The purpose of this study is to evaluate the pharmacodynamic (PD) effect, safety, and tolerability of Povetacicept in participants with generalized myasthenia gravis (gMG).

Начало: 16.04.2026 Край: 02.03.2029 Възраст: 18–80 г.

United States Vertex Pharmaceuticals Incorporated NCT07501702

Recruiting Phase 1/2

A Study to Investigate the Safety of DSP-3077 After a Unilateral Eye Injection in Male and Female Participants 18 Years of Age or Older With Retinitis Pigmentosa

Retinitis Pigmentosa

The Goal of this study is to evaluate the safety, tolerability, and clinical responses following single dose of DSP-3077. Study enrolls both male and female patients in 3 cohorts with each cohort defined by visual acuity (VA) criteria and dose level of DSP-3077. Each cohort will include 4 participants.

Начало: 16.04.2026 Край: 31.10.2032 Възраст: от 18 г.

United States Sumitomo Pharma America, Inc. NCT06891885

Recruiting

EEG Abnormalities in Adult ICU Patients With High Risk of Delirium

Delirium in the Intensive Care Unit

The purpose of this study is to assess the prevalence of EEG abnormalities on Ceribell POC EEG in adult medical, surgical, and cardiovascular ICU patients with high risk of delirium

Начало: 16.04.2026 Край: 30.09.2027 Възраст: от 18 г.

United States Ceribell Inc. NCT07485244

Recruiting Phase 1/2

A First-in-Human Study of CKD-703 in Advanced Solid Tumors and Non-Small Cell Lung Cancer

Advanced Solid Tumors Non-Small Cell Lung Cancer

This is a Phase 1/2a open-label multicenter study to evaluate the safety, efficacy, and pharmacokinetics of CKD-703 in Advanced c-Met Expressing Solid Tumors, and in MET-Amplified and c-Met Overexpressing Non-Small Cell Lung Cancer. CKD-703 is composed of a c-Met-targeting monoclonal antibody (mAb) coupled to a cytotoxic payload consisting of the anti-microtubule drug monomethyl auristatin E (MMAE); thus, CKD-703 is a novel ADC offering a highly targeted approach with potential improvement of efficacy while reducing off-target effects for patients with NSCLC and other cancers.

Начало: 16.04.2026 Край: 01.12.2029 Възраст: от 19 г.

United States Chong Kun Dang Pharmaceutical NCT07439094

Recruiting Phase 2/3

A Clinical Study Evaluating Licaminlimab for Dry Eye Disease

Dry Eye Disease (DED)

The primary objective of this study is to evaluate the efficacy and safety of the topical ophthalmic administration of licaminlimab as compared to vehicle in participants with Dry Eye Disease and a specific genotype.

Начало: 16.04.2026 Край: 01.12.2026 Възраст: от 18 г.

United States Oculis NCT07548632

Recruiting

Early Pelvic Floor Physical Therapy for Women Undergoing Pelvic Radiation for Gynecologic Malignancies

Cervical Cancer Radiation Therapy Complication Pelvic Floor Disorders

This is a single arm phase II study in which 28 patients who will be undergoing definitive pelvic external beam radiation therapy for cervical cancer will receive pelvic floor physical therapy 4 weeks after completing radiation therapy.

Начало: 16.04.2026 Край: 16.04.2030 Възраст: от 18 г.

United States University of Cincinnati NCT07447895

Recruiting Phase 1

Assessing the Safety, Tolerability, and Efficacy of APR-2020 in Pediatric and Adolescent Subjects With RPS19 Deficient Diamond-Blackfan Anemia

RPS19 Deficient Diamond-Blackfan Anemia

Brief summary The goal of this clinical trial is to learn if APR-2020 is safe and can help treat Diamond-Blackfan Anemia (DBA) in adolescents and children. The main questions it aims to answer are: * Is APR-2020 safe and well tolerated? * Does APR-2020 modify or correct an underlying genetic condition which causes DBA? * Does APR-2020 reduce or eliminate the need for blood transfusions and/or restore certain blood counts affected by DBA? Participants will: * Take the drug one time as an infusion. * Undergo two rounds of a cellular harvest procedure in which their own cells will be used in the manufacturing of their own participant-specific product. * Initially return to the clinic for two years of follow up at increasingly sparse intervals.

Начало: 16.04.2026 Край: 01.09.2028 Възраст: 2–18 г.

United States Apriligen, Inc. NCT07476183

Recruiting Phase 3

Comparing Two Different Boost Approaches in Radiation Therapy for People With Prostate Cancer

Prostate Cancer

In this study we will find out whether the use of a new type of boost approach called irreversible electroporation (IRE) is as effective as the standard boost approach of radiation therapy for people with intermediate-risk prostate cancer receiving standard stereotactic body radiotherapy (SBRT).

Начало: 16.04.2026 Край: 16.04.2029 Възраст: 18–99 г.

United States Memorial Sloan Kettering Cancer Center NCT07548164

1 … 9 10 11 12 13 … 222